



Nominations for Appointment to the Grants Working Group (GWG)

Appointment of New Members

Julie G. Allickson, PhD

Julie Allickson is the Director for Regenerative Medicine at the Clinical Center Wake Forest Institute for Regenerative Medicine in Winston-Salem, North Carolina. She received her diploma in Medical Laboratory Sciences in 1989 and her Masters degree in Medical Laboratory Sciences in 1997 from Florida International University. From 1990-1998, she served as a Laboratory Manager in the Stem Cell/Platelet Laboratory at the American Red Cross. From 2000-2004, Dr. Allickson served as the Director for cGMP Hematopoietic Cell Processing at the University of Miami, School of Medicine. During 2004-2007, she served as the Technical Director for Laboratory Operations at Cryo-Cell International, Inc. in Oldsmar, Florida. In 2007, Dr. Allickson received her Ph.D. in Health Sciences International Studies from Touro University in Cypress, CA. From 2007-2012, she served as the Vice President/Executive Officer for R&D and Laboratory Operations at Cryo-Cell International, Inc. In 2012, Dr. Allickson joined the Institute for Regenerative Medicine at Wake Forest School of Medicine as the Director for Translational Research. In 2015, Dr. Allickson took a position as the Director of the Regenerative Medicine Clinical Center at the Wake Forest School of Medicine.

Dr. Allickson has 25 years experience in Cellular Therapy, Cellular Processing and Regenerative Medicine. Her expertise focuses on the translation of regenerative medicine products including cell therapy, tissue engineering, biomaterials and devices. Her interests include the proof-of-concept stage where early discussion with regulators and clinicians are critical in moving the technology from the bench to the bedside. Dr. Allickson also has extensive experiences with critical areas in translation and clinical development such as quality assurance/quality control, regulatory affairs, process development and the GMP-complaint manufacturing facility. She has gained experience in various technical aspects of laboratory operations along with research and development activities associated with adult stem cells, including the isolation of unique stem cell populations. Dr. Allickson was also the lead in regulatory affairs for the processing laboratory of islet and hematopoietic cell products which included oversight of all Investigational New Drugs (IND) and external regulations.

Dr. Allickson is one of the founding members of the International Society of Cellular Therapy in 1992 and has been a member of the American Association of Blood Banks (AABB) for 25 years. She has presented at national and international meeting related to adult stem cells and translation. She is currently Chair of the AABB Standards Committee for Cell Therapy Product Services. Dr. Allickson is also on the Technical Advisory Board for Tissue Engineered Products under ICCBBA and the ISCT Commercialization Committee. Dr. Allickson holds eight patents and has published extensively in peer-reviewed journals.

Vassilis Koliatsos, MD, MBA

Vassilis Koliatsos is Professor of Pathology (Neuropathology) and Neurology and Associate Professor of Psychiatry and Behavioral Sciences at Johns Hopkins University School of Medicine. He is also Clinical Professor of Psychiatry in the University of Maryland and the Stulman Scholar in Clinical Neuropsychiatry and Director of the Neuropsychiatry Program at Sheppard and Enoch Pratt Hospital in Baltimore. He is Diplomate of the American Board of Psychiatry and Neurology (Psychiatry) and the UCNS Board in Behavioral Neurology and Neuropsychiatry. Dr. Koliatsos sees patients with traumatic brain injury and degenerative dementias, has been a public advocate for TBI research and patient care, and has sat for many years on the Maryland Governor's Traumatic Brain Injury Advisory Board.

Dr Koliatsos has had his own laboratory in the Division of Neuropathology of Johns Hopkins since 1990. He has worked extensively on the molecular and cellular mechanisms on neural injury and repair and has more than 100 publications in this area. He has characterized a number of nourishing peptide chemicals ("neurotrophic factors") for key populations of neurons in the brain and his stem cell work on ALS has recently entered the first clinical trial of cellular therapy for a neurodegenerative disease. His current work on TBI focuses on the chronic effects of mild and severe TBI, in particular the problem of distinguishing between the role of axonal injury versus protein (tau) disease in the outcomes of repeat concussion, mechanisms of traumatic axonal and neuronal degeneration, and the problem of translation from microscopic pathology to neuroimaging.

Dr. Koliatsos has mentored numerous pre- and post-doctoral students and has taught residents in neurology and psychiatry on clinical neurosciences and neuropsychiatry. He serves on the faculty of the Ph.D. graduate program of Pathobiology of Disease and has also served in the Ph.D. Neuroscience program at Johns Hopkins. Dr. Koliatsos has been awarded the Leadership and Excellence in Alzheimer's disease Award and the Javits Neuroscience Investigator Award, both from NIH.

Pradeep Mammen, MD, FACC, FAHA

Dr. Mammen is a clinician-scientist with clinical expertise in advanced heart

failure, ventricular assist devices and heart transplantation. From a clinical perspective, he is one of only approximately 500 adult cardiologists in the United States board certified in advanced heart failure/heart transplantation and obtained his clinical training at UT Southwestern Medical Center under the guidance of Clyde Yancy MD (currently Chief of Cardiology at Northwestern University). His clinical experience over the past 20 years has enabled him to acquire a significant amount of expertise in the management of all forms of advanced heart failure. Secondary to additional training Dr. Mammen received in molecular cardiology, he has also developed a unique interest as well as expertise in caring for neuromuscular patients who develop a cardiomyopathy. In fact with the approval of the UTSW Dean (J. Gregory Fitz, MD) and the Chief of Cardiology (Joseph Hill, MD/PhD), Dr. Mammen founded and became the Medical Director of the UTSW Neuromuscular Cardiomyopathy Clinic in June of 2010. Although there are only six adult clinics in the United States exclusively dedicated to addressing the cardiovascular needs of patients with neuromuscular disorders, the UTSW Neuromuscular Cardiomyopathy Clinic is one of only two clinics in the country run by a board-certified adult heart failure cardiologist. Referrals to this clinic have exploded over the past two years and this demonstrates the great clinical need for such a clinic in the community. Finally, the Clinic services as a platform for translational studies focused on novel therapies directed towards muscular dystrophy patients. These studies are aimed at improving both the overall care as well as the cardiovascular care that is provided to this unique patient population. In fact, in September of 2015 the NIH awarded UT Southwestern a Senator Paul D. Wellstone Muscular Dystrophy Cooperative Research Center, one of only six Centers in the country. Dr. Mammen and Dr. Eric Olson service as the Co-Directors of this Center, which is focused on a identifying a novel therapeutic approach for treating Duchenne muscular dystrophy.

In keeping with Dr. Mammen's clinical interest in the treatment and management of patients with heart failure, he has developed significant scientific interest in investigating the molecular mechanisms underlying skeletal and cardiac myopathies. Dr. Mammen seeks to become a national leader in biomedical innovation and discovery in order to improve the quality and longevity of patients with skeletal and cardiac myopathies. Therefore, as part of his academic pursuits, Dr. Mammen runs a NIH R01-funded molecular laboratory and his laboratory undertakes mechanistic studies to enhance our understanding of myogenesis and muscle regeneration. The Mammen Laboratory has received research grants from the American Heart Association, GlaxoSmithKline Research Foundation, National Institute of Health, Pfizer Inc., and Reynold's Foundation. Finally, since joining the UTSW faculty Dr. Mammen has successfully administered numerous grants, formed strong collaborations with several key clinicians and scientists at UT Southwestern (i.e. Drs. Rhonda Bassel-Duby, James deLemos, Mark Drazner, Joseph Hill, Helen Hobbs, Eric Olson, Milton Packer, Beverly Rothermel, Hesham Sadek, Jay Schneider, and

Phil Shaul), discovered a novel signaling pathway within myocytes and produced 44 high-quality peer-reviewed publications to date.

Michael Murphy, MD

Michael Murphy is a native of New York and received his medical degree from the College of Physicians and Surgeons of Columbia University where he was selected for Alpha Omega Alpha honor medical society during his junior year. Dr. Murphy completed his general surgery training at the Brigham and Women's Hospital, Harvard Medical School where he was chosen for the Francis Daniels Moore Senior Resident Award. During his residency he spent two years in research in the cardiac surgery laboratory at the Harvard Medical School studying heart failure and skeletal muscle augmentation of ventricular function. Dr. Murphy continued on as faculty as the Assistant to the Surgeon in Chief at the Brigham and Women's Hospital and Instructor in Surgery at Harvard Medical School before continuing his fellowship training in vascular surgery at Duke University Medical Center. Dr. Murphy joined the faculty of the Indiana University School of Medicine in 2005 where he serves as Associate Professor of Surgery and Cellular and Integrative Physiology (tenured in research), Clinical Director for the Vascular and Cardiac Adult Stem Cell Therapy Center, Director of the IU Center for Aortic Disease, and Executive Committee of the Cardiovascular Cell Therapy Research Network for the National Heart, Lung, and Blood Institute.

Dr. Murphy's interest is in stem cell physiology and he designed and conducted the first clinical trial in the U.S. using autologous bone marrow cells for peripheral arterial disease in 2003. Dr. Murphy has multiple grants from the National Institutes of Health, the Veterans Administration, and the Strategic Research Initiatives including a \$63 million program grant (NIH 1UM1HL113457-01) that is focusing on clinical research in stem cell therapies for cardiovascular disease. Dr. Murphy has authored over sixty publications and is currently the national Principal Investigator on four stem cell trials in arterial and aortic disease. He serves as Director of the IU Health Center for Aortic Disease and Clinical Director the Vascular and Cardiac Adult Stem Cell Therapy Center.

Dr. Murphy belongs to the American Medical Association, American College of Surgeons, American Heart Association, International Society for Stem Cell Research, North American Vascular Biology Organization, American Society of Gene and Cell Therapy, International Society for Stem Cell Research, Society for Vascular Surgery, and Association for Academic Surgery.

Dr. Murphy joined the U.S. Army Reserve in 2004 and served two tours in Iraq as a vascular and trauma surgeon, receiving the Army Commendation Medal, Meritorious Service Medal, and Bronze Star for his service. He now resides in Carmel, Indiana with his wife, Laura, and their family.

Rajiv Raja, PhD

Rajiv Raja is Director of Translational Sciences and Pharmacogenomics at MedImmune/Astra Zeneca. Prior to that he was Group Leader in the Clinical Assays and Technologies Group in Oncology Biomarker Development at Genentech. He was also a scientist at CIRM's facility at Stanford and Director, Molecular Biology R&D at Arcturus Biosciences.

Dr. Raja specializes in biomarker development and has published numerous papers on the subject. He has seventeen years of experience developing, validating and implementing molecular diagnostic assays and technologies for clinical studies, creating clinical diagnostic assays in collaboration with partners such as Roche Molecular Diagnostics (RMS), Foundation Medicine (FM) and Ventana. He is experienced in developing biomarker assessment strategies for limited/degraded clinical samples such as FFPE tissues, core biopsies, plasma and fine needle aspirates, and has developed and implemented diagnostic tests in CLIA/CAP certified labs to enable diagnostic testing for clinical trials. Currently he manages a group of scientists implementing pharmacogenomic approaches to drug development.

Dr. Raja obtained his Ph.D. in molecular genetics from Oklahoma State University and did postdoctoral studies at the University of Illinois at Urbana-Champaign.

Reappointment of Scientific Members to the Grants Working Group

Grants Working Group Members originally appointed in 2008-09 have terms that are now expiring or just expired. We are seeking the reappointment of the individuals listed in the table below. Their updated biographies follow. In accordance with the rules set forth by Proposition 71, reappointments should be staggered into thirds, each with a 2, 4, or 6-year term.

Proposed Reappointments to GWG

Last	First	Term	Expertise
Boulton	Michael	6	Retinal Disease; Stem Cell Biology
Matsui	William	6	Stem Cell & Cancer Stem Cell Biology; Clinical Oncology
Waldmann	Herman	4	Transplantation Tolerance; Therapeutic use of Monoclonal Antibodies

Michael Boulton, PhD

Michael Boulton is Professor and Director of Basic and Translational Research in the Department of Ophthalmology at the Glick Eye Institute, Indiana University. He was previously a Professor in the Department of Anatomy and Cell Biology at the University of Florida. He moved to the University of Florida from the University of Texas Medical Branch where he was Director of the AMD Center. Dr. Boulton has a distinguished international record for his investigations into the pathophysiology of the retina. He received his B.S. degree in Microbiology with Chemistry at the University of Reading, and his Ph.D. from Polytechnic of Central London.

His research group has two main research areas: age-related changes in the retina and retinal neovascularization. Dr Boulton has a large number of research projects in progress which include nanotechnology to eliminate lipofuscin from the aged eye; investigating the contribution of mitochondrial dysfunction and autophagy dysregulation to age-related macular degeneration; hematopoietic stem cell repair of the damaged retina; targeting γ -secretase in the regulation of angiogenesis; investigating the role of bone marrow-derived progenitor cells in vascular repair; and developing new strategies for the regulation of angiogenesis.

Dr. Boulton has over 200 publications and has a long history of research support including two current RO1's. He has given over 40 plenary lectures at international conferences. He currently sits on a number of review committees and is a scientific advisor to a number of other agencies. Dr Boulton is on the editorial board of five international journals and plays a major role in the organization and development of a number of professional societies. He has also made a significant contribution to teaching graduate and undergraduate students and has played a major part in the organization and development of graduate education.

William Matsui, MD

Bill Matsui joined the faculty of the Department of Oncology at the Johns Hopkins University School of Medicine in 2001 and is currently a Professor in the Division of Hematologic Malignancies. He received his undergraduate degree in Biochemistry from Harvard College in 1989 and his medical degree from the University of California at San Francisco in 1995. He completed his residency training in internal medicine at the University of Washington in Seattle and his clinical training in Medical Oncology at Johns Hopkins. During his fellowship, Dr. Matsui carried out his postdoctoral research in the laboratory of Dr. Richard Jones where he studied cellular pathways and factors involved in tumor cell differentiation. His postdoctoral training was supported by fellowships from the Leukemia and Lymphoma Society and the American Society of Clinical Oncology. He has been awarded the George Santos Research Award from the Leukemia and Lymphoma Society, the Clinician Scientist Award from Johns Hopkins University, and teaching awards from the Departments of Oncology and Medicine. He is also an elected member of the American Society of Clinical Investigation. Dr. Matsui clinically specializes in caring for adults with hematologic malignancies and directs the Johns Hopkins Multiple Myeloma Program.

Dr. Matsui's research has focused on studying cancer stem cells and their role in clinical oncology. His laboratory first identified cancer stem cells in the plasma cell malignancy multiple myeloma in 2003. He has gone on to further characterize these cells and found that several pathways active in normal stem cells, such as developmental signaling pathways, telomerase, and retinoid signaling, are aberrantly active in cancer stem cells in multiple myeloma, lymphomas, leukemias, and brain tumors. He has also studied the role of developmental signaling pathways in regulating both normal hematopoiesis and myeloid leukemias. His lab also currently studies cancer stem cells in pancreatic adenocarcinoma and has found they express mesenchymal features that may facilitate their metastatic spread. Dr. Matsui's research has been funded by the NIH and the National Cancer Institute, The International Myeloma Foundation, The Sidney Kimmel Foundation for Cancer Research, The Gabrielle's Angel Foundation, The Lustgarten Foundation, The Multiple Myeloma Research Foundation, and the Leukemia and Lymphoma Society. Furthermore, the Matsui lab is firmly focused on translational research and has been successful in developing novel therapies that target cancer stem cells in hematologic malignancies. Currently over a dozen clinical trials have been initiated based upon the preclinical work carried out by his laboratory.

Herman Waldmann, FRS

Herman Waldmann is Emeritus Professor of Pathology and former Head of the Sir William Dunn School of Pathology at the University of Oxford. An immunologist, he is best known for his work on therapeutic monoclonal antibodies, particularly Campath-1, now licensed as Lemtrada for the treatment of Multiple Sclerosis.

Dr. Waldmann received his undergraduate and graduate degrees from the University of Cambridge and began his scientific career there in the Department of Pathology. He became Head of the Immunology Division and was named Kay Kendall Chair in Therapeutic Immunology. It was at Cambridge that he studied mechanisms by which cells of the immune system could interact to mount immune responses. This early work led him to become interested in immunological tolerance and achieving tolerance for therapeutic purposes.

Since 1980 he has been funded by the UK Medical Research Council and European Research Council to study mechanisms of transplantation tolerance and strategies to achieve this both experimentally and clinically. In 1985 he published the first studies to show that short courses of CD4 antibody therapy could bring about long-term immunological tolerance to foreign proteins, and this work led to the first demonstrations of transplantation tolerance resulting from short-term antibody blockade.

His mechanistic studies of tolerance uncovered a role for regulatory T-cells in infectious tolerance which was published in a seminal paper in Science in 1993. The strategies emerging from his laboratory since that time have been based on the use of therapeutic antibodies to enhance regulation over conventional T-cell immunity.

In order to apply antibodies clinically Waldmann developed the first academic antibody therapeutic manufacturing facility. He and his team were able to apply clinical-grade antibodies in a wide range of probing therapeutic studies that enabled them to develop a series of humanized antibodies (CD52, CD3, CD4 and others) which have since been transferred to the pharmaceutical industry.

His team's work since 1971 has resulted in more than 500 publications, the majority directed to therapeutic antibodies and their mechanisms of action. These contributions have led to his election to the Royal Society in 1990. Professor Waldmann is the recipient of the Jose Carreras Medal of the European Hematology Society, the Juvenile Diabetes Research Foundation Excellence in Clinical Research Award (2005), University of Iowa Distinguished Professor Lecture, Thomas E Starzl Prize in Surgery and Immunology, Scrip Lifetime Achievement award (2007) and an Honorary Doctorate (DSc) University of Cambridge (2008).